With Managed Care, Nurses Face Greater Exposure to Liability
May 1st 1999ALEXANDRIA, Va-Although nurses traditionally have not been sued individually for malpractice, changes in technology, medical practice, and medical economics have made them increasingly vulnerable to being named in litigation, according to Susan B. Fink, RN, JD, an attorney with Koskoff, Koskoff & Bieder, PC, of Bridgeport, Conn.
Making Music in the Hospital Aids Rehab, Raises Spirits
May 1st 1999COLUMBUS, Ohio-Many aspects of cancer patient care can be improved or enhanced with the use of music therapy, said Deforia Lane, PhD, resident director of music therapy, University Hospitals of Cleveland-Ireland Cancer Center/Rainbow Babies & Children’s Hospital, and assistant clinical professor of medicine, Case Western Reserve University. Dr. Lane, a board-certified music therapist, spoke at a conference on cancer survivorship sponsored by the Ohio State University’s James Cancer Center and Solove Research Institute.
Preop Combined Modality Treatment, Promising Oral Agents
May 1st 1999ORLANDO-The new frontiers in colorectal cancer include multimodality treatment used preoperatively and a new group of oral fluoropyramidine drugs, according to presentations at the Society of Surgical Oncology’s 52nd Annual Cancer Symposium.
Anesthesiologists Have Increasing Role in Managing Pain
May 1st 1999NEW YORK-In recent years, the practicing anesthesiologist has become more involved in the management of pain and has to be aware of the increasing number of treatments available, said Carol A. Warfield, MD, chief, Division of Pain Services, Beth Israel Deaconess Hospital, Boston.
Grapefruit Juice-Vinblastine Interaction
May 1st 1999ALEXANDRIA, Virginia-Drinking grapefruit juice with certain medications, including at least one widely used in cancer treatment, may inhibit their absorption, according to an in vitro study in the April 1999 issue of Pharmaceutical Research, a publication of the American Association of Pharmaceutical Scientists (AAPS).
Dye, Intradermal Radiocolloid Find the Sentinel Node
May 1st 1999ORLANDO-Both dye and radioactive tracer are required for finding sentinel lymph nodes most accurately in patients with operable breast cancer, but small intradermal injections of the tracer can be used instead of intraparenchymal tracer injections, researchers from Memorial Sloan-Kettering Cancer Center reported at the Society of Surgical Oncology’s Annual Cancer Symposium.
Patients’ Bill of Rights Remains on Congressional Agenda
May 1st 1999FORT LAUDERDALE, Fla-Before talking about the various “patients’ bill of rights” legislation before the US Congress, Harry D. Holmes, PhD, played the theme from the movie Back to the Future. “That’s what it seems like in managed care reform, since all of these bills were filed last year and here they are again, both in the House and the Senate.”
US Cancer Incidence, Mortality Show Overall Decline
May 1st 1999WASHINGTON-Overall cancer incidence and mortality have continued to decline in the United States, but incidences of some cancers continue to rise, and significant differences in both incidence and mortality persist among different racial and ethnic groups.
Cannabinoid Drugs May Offer Symptom Relief
May 1st 1999WASHINGTON-During the past 16 years, researchers have developed data that suggest cannabinoid-based drugs may be effective for a variety of medical uses, including pain relief, antiemesis, and appetite stimulation in cancer patients, an Institute of Medicine (IOM) committee has concluded. It warned, however, that such medical uses carry some risks, particularly the harmful effects of smoking marijuana, which it discouraged as a means of delivering medications.
Thymus May Hold Clue To Rebuilding Immune System After HIV
May 1st 1999Discovery of a marker that allows tracking of thymus function also shows how the adult immune system might repair itself after being damaged by the human immunodeficiency virus (HIV), UT Southwestern Medical Center at Dallas scientists report
Task Force to Evaluate Vitamins, Pharmacologics as Cancer Prophylaxis
May 1st 1999ROCKVILLE, Md-Two cancer-related topics are among four new evaluations the Agency for Health Care Policy and Research (AHCPR) has asked the U.S. Preventive Services Task Force to make. The task force is an independent panel of preventive health experts that evaluates the effectiveness of a wide range of clinical preventive services.
NCI Program Aims at Reducing Cancer Burden Among Minorities, the Poor
May 1st 1999BETHESDA, Md-The National Cancer Institute (NCI) has earmarked $30 million for use over the next 5 years to support a group of projects that will unite research scientists and community leaders in efforts to address disparities in national cancer rates among minorities and other underserved groups.
Legislation Would Carve Out Cancer From HCFA-Proposed APCs
May 1st 1999ALEXANDRIA, Va-“The Health Care Finance Agency’s plan to reimburse for outpatient Medicare cancer treatment according to ambulatory payment classifications (APCs) would have a crippling effect on research and development of new drug therapies and lower the quality of care for present and future cancer patients,” Congressman Gene Green, Representative of the 29th District of Texas in the US House of Representatives, said at the Annual Meeting of the Association of Community Cancer Centers (ACCC).
NCI Announces Sites of First Endostatin Phase I Studies
May 1st 1999BETHESDA, Md-The first human trials of the antiangiogenesis drug endostatin will take place at the University of Wisconsin-Madison and the University of Texas M.D. Anderson Cancer Center. The National Cancer Institute (NCI), which will sponsor the phase I trials, said that the studies will begin in late summer or early fall. Protocols for the two studies had not been worked out at the time of the NCI’s announcement.
New Agents Have Altered ‘Therapeutic Paradigm’ of NHL
May 1st 1999We are entering an extraordinary era in the treatment of patients with indolent non-Hodgkin’s lymphomas (NHL). Several decades were devoted to expending resources on comparing combinations and permutations of conventional agents, but with no beneficial impact on survival.
Danish Perspectives in Oncology: Profiles From Aarhus
May 1st 1999While in Denmark under an ASTRO/ESTRO fellowship travel grant, Dr. Brian Kavanagh spoke with a number of oncologists at the University of Aarhus about their research and the practice of oncology in Denmark. In this essay, he skillfully weaves Danish history, philosophy, customs, and landscape into his interviews with four eminent Danish physicians.
Cost Modeling for Alternate Routes of Administration of Opioids for Cancer Pain
May 1st 1999The economic considerations relative to neuraxial infusion can be looked at with different types of economic models, including cost-minimization, cost-effectiveness, and cost-benefit analyses. A theoretical predictive model
A 15-Year-Old Boy With Primitive Neurectodermal Tumor
Dr. Peter Staats presented the case of a 15-year-old, 40-kg boy with a primitive neurectodermal tumor located in
Neuraxial Infusion for Pain Control: When, Why, and What to Do After the Implant
May 1st 1999Neuraxial infusion therapy is an excellent option for selected patients with severe pain. Both epidural and intrathecal systems can be effective for multiple pains and are titratable, nondestructive, and very safe.